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This prospective patient-preference study examined the effectiveness in practice of methadone versus buprenorphine maintenance treatment
and the beliefs of subjects regarding these drugs. A total of 361 opiate-dependent individuals (89% of those eligible, presenting for treatment
over 2 years at a drug service in England) received rapid titration then flexible dosing with methadone or buprenorphine; 227 patients chose
methadone (63%) and 134 buprenorphine (37%). Participants choosing methadone had more severe substance abuse and psychiatric and
physical problems but were more likely to remain in treatment. Survival analysis indicated those prescribed methadone were over twice as likely
to be retained (hazard ratio for retention was 2.08 and 95% confidence interval [CI] = 1.49–2.94 for methadone vs. buprenorphine), However,
those retained on buprenorphine were more likely to suppress illicit opiate use (odds ratio = 2.136, 95%CI = 1.509–3.027, p b .001) and achieve
detoxification. Buprenorphine may also recruit more individuals to treatment because 28% of those choosing buprenorphine (10% of the total
sample) stated they would not have accessed treatment with methadone. © 2010 Elsevier Inc. All rights reserved.Keywords: Buprenorphine; Methadone; Maintenance; Treatment retention; Opiate dependence1. Introduction
Opiate maintenance treatment with both methadone
(MMT) and buprenorphine (BMT) has been shown to
reduce the negative consequences of opiate dependence:
reducing mortality, illicit drug use, criminal behavior, and
spread of blood borne viruses and improving physical and
mental health and social functioning (National Institute for
Clinical Excellence [NICE], 2007).
NICE guidance (NICE, 2007) in the UK recommends the
availability of both and states that where both are “equally⁎ Corresponding author. The Weavers Centre, Hellesdon Hospital,
Drayton High Road, Norwich, NR5 6BE Norfolk, UK. Tel.: +44 01603
786786; fax: +44 01603 786700.
E-mail address: hayley.pinto@nwmhp.nhs.uk (H. Pinto).
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doi:10.1016/j.jsat.2010.07.009appropriate,” methadone should be first-line, based on its
reduced cost and evidence from existing trials (summarized
in the recently updated Cochrane review by Mattick,
Kimber, Breen, & Davoli, 2008) that retention with
methadone is better; whereas suppression of illicit opiate
use is equivalent with either treatment.
However, many of the trials on which the Cochrane
review was based (Fischer et al., 1999; Johnson et al., 2000;
Lintzeris et al., 2004; Mattick et al., 2000; Neri et al., 2001;
Petitjean et al., 2001; Strain, Stitzer, Liebson, & Bigelow,
1994) used relatively low doses of buprenorphine with slow
inflexible induction, and this may have skewed the retention
rates in favor of methadone. In addition, there is virtually no
research identifying features that predict a better outcome
with either drug or directly examining other outcomes, such
as social functioning or psychological health, to guide the
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appropriate. The decision as to which drug to prescribe is
therefore currently based on predicted differential effects
based on the known pharmacology of the drugs and
clinicians' opinions and patient choice, about which very
little is known.
Methadone is a long-acting full agonist at the mu opiate
receptor. Consequently it can offer a degree of persisting
intoxication (including a degree of sedation), which may be
attractive to some and limiting to others. Continued use of
illicit heroin is common, limiting the reduction in harm
associated with treatment. It is capable of producing fatal
respiratory depression and prolongs the QTc interval (Fanoe,
Hvidt, Ege, & Jensen, 2007), contributing significantly to
opiate-related deaths (Auriacombe, Franques, & Tignol,
2001). Withdrawal from methadone is believed by many
opiate users to be worse than heroin withdrawal. This, in
addition to the requirement for daily dosing, leads some to
view methadone simply as an “alternative addiction” that
prolongs dependency. These beliefs form part of a negative
“lore” among some heroin users regarding methadone,
which has been shown to inhibit some individuals from
engaging with treatment (Kayman, Goldstein, Deren, &
Rosenblum, 2006; Schwartz et al., 2008).
Buprenorphine's receptor profile as a partial agonist with
high affinity at the opiate receptors should in theory predict
superiority over methadone in terms of safety (due to a
ceiling effect on respiratory depression; Walsh, Preston,
Stitzer, Cone, & Bigelow, 1994), suppression of illicit opiate
use (due to increased receptor blockade), improvements in
social functioning (due to reduced sedation), and progression
to detoxification (due to greater ease of withdrawal).
Translation of theory into practice has however been
patchy. To date, studies have shown no consistent benefit in
terms of suppression of illicit opiate use or social functioning.
Progression to detoxification has not been examined.
Buprenorphine does appear to be safer than methadone for
those individuals who remain in treatment (Auriacombe et al.,
2001; Bell, Butler, Lawrence, Batey, & Salmelainen, 2009),
but the impact of reduced retention rates cannot be ignored in
this context, as mortality rates of injecting drug users are
considerably higher when not in treatment (Gronbladh,
Ohlund, & Gunne, 1990) as are levels of criminal activity
and chaotic social functioning that impact on their immediate
families (including their children) and society in general.
Negative aspects of buprenorphine include the potential
to precipitate withdrawal symptoms at induction. In addition,
the sublingual tablet tastes unpleasant and dissolves slowly,
reducing its acceptability and making supervision of its use
more difficult. The practice of crushing and injecting the
tablets also leads to significant harm.
Whether the availability of an alternative has attracted
into treatment individuals averse to methadone has not been
examined; however, since the introduction of BMT to the
UK, the number of prescriptions for both drugs has increased
(NTA, 2007), implying that more individuals are beingtreated rather than that buprenorphine has replaced metha-
done in existing patients.
There are no existing trials comparing BMT and MMT
based in the UK, which differs in important respects to many
other countries, partly due to the free availability of both
treatments in most areas and a comprehensive benefit
system. These factors contribute to difficulty recruiting to
randomized controlled trials to the extent that their
generalizability can be severely compromised. A local pilot
study found that the number of eligible subjects prepared to
accept randomization constituted less than 2% (Pinto,
Rumball, Maskrey, & Holland, 2008). Randomization and
effective blinding also (in theory) divorce the results from
patients' expectations about the effectiveness, for them as
individuals, of the two alternative treatments. This could be
predicted to have a powerful effect on their outcome in
routine clinical practice where patients do know which
treatment they are receiving.
The authors were therefore interested to explore the
effectiveness of BMT versus MMT in UK clinical practice
where treatment is freely available, and patient choice is now
supported (NICE, 2007), outside the narrower confines of a
randomized control trial. Effectiveness was measured in
terms of retention, achievement of opiate detoxification, and
suppression of illicit opiate use. Secondary outcomes
included measurement of social functioning and psycholog-
ical health. Uniquely, comprehensive baseline data were
gathered regarding participants' history, detail on reasons for
choice, and beliefs about both treatments to explore the basis
on which patients chose between these drugs and establish
whether any preexisting features or expectations predicted
outcomes in treatment.2. Materials and methods
2.1. Subjects and setting
Participants were recruited between October 2005 and
October 2007 from three sites within one community drug
service covering a large rural area and two urban centers in
Norfolk. All new patients who were opiate dependent (based
on clinical assessment and at least two urine toxicology
screens), not prescribed either study drug for the preceding
month, requesting maintenance treatment (and for whom it
was appropriate) were invited to participate.
2.2. Interventions
Treatment occurred according to usual clinic practice and
was not influenced by participation in the trial. Patients
chose either methadone or buprenorphine in collaboration
with the treating clinician. Induction in line with national
guidance (Orange book) on to the drug of choice occurred
over a titration period of 3 days during which the patient
attended daily for monitoring. Doses were given under
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course of a day. Following titration, most patients continued
to receive their medication under supervision on most days
either in the clinic or a community pharmacy. In line with
normal UK practice, take-home doses were introduced on an
individual basis when it was felt appropriate and safe to do
so. Alteration to doses either up or down could be negotiated
with the treating clinician at any point. Where general
practitioners were willing, prescriptions for stable subjects
were transferred to primary care.
Patients were discharged from the trial if they failed to take
their prescription for more than 7 days or were discharged
from the service. Criteria for discharge were production of a
tampered urine sample; serious aggressive behavior to staff or
on the premises; illicit drug use on the premises; and failure to
engage constructively with therapy after appropriate attempts
by workers to facilitate engagement.
In addition to pharmacological treatment, subjects were
seen individually by key workers, initially weekly then at a
frequency negotiated with the subject according to their
needs. Key workers act as care coordinators, providing
individual support sessions that are not structured therapy.
This includes signposting and assistance with a range of
needs, for example, accessing housing support, education
and employment advice, and finance and benefits advice.
They act as advocates for the patients and monitor physical
and mental health, making referrals to additional services as
appropriate. Medical review occurs in the service six
monthly or on request of the key worker.
2.3. Measures
Detailed baseline data were collected on a very wide
variety of demographic and background variables (N50). In
addition, at entry, participants completed a detailed ques-
tionnaire regarding their knowledge and beliefs about the
two alternative drugs and their reasons for their treatment
choice. The following beliefs or knowledge were explored:
taste of drug, likelihood of experiencing withdrawals when
starting on the drug, effect on craving, blocking effect on
heroin use, overdose risk, level of intoxication (sedation,
clear headedness, emotional numbing), stigma, ease of
detoxification, and degree to which the drug was perceived
as an alternative addiction.
The primary outcome was retention in treatment at 6
months or successful detoxification (i.e., a “positive”
outcome). Successful detoxification was defined as patients
who were recorded to be opiate-free at the point of discharge
from the service during the trial. Subjects were considered as
“not retained” in the trial if they failed to take their
maintenance drug for seven consecutive days. A secondary
outcome was suppression of illicit drug use evidenced by
urine toxicology. The frequency of urine sample testing in the
service is flexible according to the level of engagement and
suspected or reported illicit drug use. This could have led to a
wide variation in the numbers of available samples for patientsin the trial. To eliminate this discrepancy and prevent possible
bias, it was decided at the outset to obtain copies of the first
urine toxicology report each month only from the clinical
notes. Christo inventories (a measure of social functioning,
addictive and risk behavior, and treatment engagement;
Christo, Spurrell, & Alcorn, 2000) were completed by key
workers at baseline, 3 months, and 6 months. Additional self-
report data on alcohol use (brief Alcohol Use Disorder
Identification Test, brief AUDIT), illicit drug use (adapted
Office for National Statistics questionnaire), and psycholog-
ical health (Brief Symptom Inventory [BSI]) were collected at
baseline, 3 months, and 6 months.
2.4. Sample size
A pilot study (n = 42) demonstrated approximately equal
numbers chose each drug and suggested that methadone
retained about 15% more subjects at 6 months (68% vs.
55%)13. A total sample size of 326 was calculated to be
sufficient, with 80% power, to detect a difference of 55%
versus 70% using the chi-squared test at a 5% significance
level. After the trial began (at n = 109), recruitment
demonstrated that methadone was the more popular choice
(2:1 ratio). We therefore recalculated the sample size at that
point taking account of this imbalance, which raised the
sample size required to 363 patients.
2.5. Analysis
Because this was a nonrandomised study, baseline data
were compared to investigate differences between groups.
Retention was compared between groups using Fisher's
exact test. To control for possible confounders, all variables
measured at baseline that exhibited both (a) a p value less
than .2 when tested for bivariate association with the
primary outcome and (b) a p value less than .2 when tested
between groups were included as independent variables in a
logistic regression to obtain an adjusted odds ratio (OR). In
addition, the Cox proportional hazards model was used to
compare time retained between groups, using the same
potential confounders as in the logistic regression to provide
adjusted estimates. Analyses were conducted on an
intention-to-treat basis, classifying participants according
to the drug they first chose, then repeated on a per-protocol
basis analyzing participants according to the drug they
completed the study on. Finally, a sensitivity analysis was
conducted, broadening our definition of retention to include
those who were transferred on a prescription to another drug
treatment service.
Urine results were analyzed as repeated measures to
allow for correlation between results on each patient. In
addition, sustained abstinence from illicit use was inves-
tigated by comparing groups in terms of the proportion
providing six negative urines, or five negative and one
missed urine. Changes in Christo, BSI, and drug and
alcohol use scores for those retained at follow-up were
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corresponding baseline measure.
Within each drug category, we also investigated the effect
on outcome of participants' baseline knowledge, beliefs, and
reason for choice of drug. Initially, this was by a univariate
analysis for each drug to explore whether those with a
positive outcome had different beliefs to those with a
negative outcome. We then planned to undertake a
multivariate analysis if a number of beliefs appeared
potentially predictive of success.
2.6. Ethical approval
Ethical approval for this study was obtained from the
Norwich District Research Ethics Committee. Informed
consent was obtained from all participants.
3. Results
3.1. Participants
A total of 555 clients presented for maintenance
treatment, of whom 105 were excluded (see Fig. 1) and
44 were not approached by our study researcher due to
logistical difficulties covering three sites. Of the remaining
407 clients, 361 (89%) agreed to enter the study. Of these,
227 (63%) chose methadone, and 134 (37%) chose
buprenorphine (Fig. 1).
3.2. Baseline comparison
The two groups appeared to be well matched (Table 1).
Most were White, unemployed, male polydrug users
involved in criminal activity who had been dependent on
heroin (which most injected) for an average of 10 years.
Most described a history of childhood adversity, with more
than one third reporting some form of abuse and two thirds
reporting a parent with an alcohol problem. Most participants
also had poor physical and mental health.
Some differences were noted. Those choosing MMTwere
more likely to be female (28% vs. 19%), to have resident
children (23% vs. 14%), to have a drug-using partner (62.6%
vs. 49.4%), to express a higher level of psychological distress
(BSI's Global Symptom Index 53.6 vs. 50.3), to have a
physical diagnosis (51% vs. 41%), and to be taking some
medication for that condition. They had slightly poorer social
functioning reflected in higher average Christo scores (11 vs.
9.7), were more likely to be using heroin intravenously (68%
vs. 55%) at a higher reported dose (0.8g vs. 0.5g), and to have
positive urine toxicology for cocaine.
3.3. Doses
Mean dose of buprenorphine at the end of Day 1 of
titration was 6.9 mg (range = 2–12 mg), 9.9 mg (range = 2–
20 mg) at the end of Day 2, and 11.3 mg (range = 4–20) atthe end the Day 3. This compared to a mean of 50.7 mg Day
1 (range = 0–135 mg), 63.8 mg Day 2 (range = 5–160 mg),
and 69.6 mg at the end of Day 3 for methadone (range = 5–
170 mg). Mean maximum doses throughout the trial were
73.3 mg of methadone (range = 10–170 mg) and 11.7 mg of
buprenorphine (range = 4–20 mg). More patients on
buprenorphine chose to reduce their dose during the trial
rather than to increase it.
3.4. Positive outcome (i.e., retention or detoxification)
At 6 months, significantly fewer of those selecting BMT
(50%), than those selecting MMT (70%), achieved a positive
outcome (p b .001; Fisher's exact test). This equates to a
relative risk of a positive outcome for BMT of 0.71 (i.e., a
reduced probability of a successful outcome) or an OR of
0.43 (95% confidence interval [CI] = 0.20–0.67, p b .001).
This OR decreased (i.e., worsened) to 0.34 (95% CI = 0.20–
0.59, p b .001) after adjusting for potential confounders.
Almost identical results were found in a per-protocol
analysis adjusting for seven participants who swapped
from buprenorphine to methadone soon after entering the
study. The difference in positive outcome observed, favoring
methadone, was wholly due to the difference in retention
rates as detoxification was achieved by more of those
receiving buprenorphine (10/134, 7.5%) than those receiving
methadone (1/361, 0.3%).
3.5. Survival analysis
A survival analysis to 6 months further demonstrated the
marked difference in retention (see Fig. 2). A log-rank test
comparing methadone to buprenorphine indicated markedly
different survival functions (p b .001). The unadjusted
hazard ratio for retention on methadone compared with
buprenorphine over the 6 months of the study was 2.08 (95%
CI = 1.49–2.94, p b .001). Adjusting for the same potential
confounders as in the main analysis raised this hazard ratio to
2.27 (95% CI = 1.56–3.30, p b .001). Reasons for
noncompletion are shown in Table 2.
3.6. Investigating the relationship between dose of drug
and retention
Fig. 3 shows the relationship observed between the dose
prescribed and the retention rates. Doses of methadone
greater than 60 mg appeared most effective, with increasing
dose yielding improved retention. In contrast, although a dose
of at least 8 mg of buprenorphine appeared necessary, further
increases above this level did not appear to improve retention.
3.7. Analysis of predictors for retention in treatment at
6 months
We undertook an analysis to identify which baseline
factors predicted retention in treatment at 6 months.
Fig. 1. CONSORT statement: flowchart describing progress of participants through the SUMMIT trial.
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appeared to be related to retention, in addition to preferred
drug. When these were incorporated simultaneously into amultiple logistic regression, 7 were significant. The
predictor of retention with greatest OR was preferred
drug (MMT), this was also highly statistically significant
Table 1
Baseline comparison
Methadone (n = 227)
n (%) or M (SD)
Buprenorphine (n = 134)
n (%) or M (SD)
p value (Fisher's exact or
Mann–Whitney test)
Male 163 (71.8%) 108 (80.6%) .08
Age 33.1 (7.9) 32.4 (7.7) .48
White 217 (96.9%) 128 (95.5%) .57
Age left education 15.6 (1.7) 15.8 (2.6) .98
In a relationship 113 (49.8%) 72 (53.7%) .51
Resident children 52 (23.2%) 18 (14.0%) .04
Accommodation
Stable 151 (66.8%) 94 (70.2%) .73
Temporary 68 (30.1%) 35 (26.1%)
Homeless 7 (3.1%) 5 (3.7%)
Employed 26 (11.5%) 18 (13.5%) .62
Any previous convictions 206 (90.8%) 115 (86.5) .22
Any previous custodial sentences 147 (64.8%) 85 (63.4%) .82
Parent drug user 38 (17.0%) 19 (14.7%) .65
Parent had alcohol problem 146 (65.2%) 79 (60.3%) .36
Parent had psychiatric disorder 77 (34.5%) 41 (31.5%) .64
Parents separated 114 (51.4%) 74 (57.4%) .32
Time in care as a child 58 (25.8%) 42 (31.6%) .27
Abused as a child 83 (37.1%) 51 (38.9%) .74
Current psychiatric diagnosis 122 (54.0%) 61 (45.9%) .16
Current physical diagnosis 115 (50.7%) 54 (41.2%) .10
No. medications 1.5 (2.0) 1.1 (1.5) .02
On BDZ or Z drug 67(30.0%) 32 (24.2%) .27
Taking any psychotropic drug 101 (44.9%) 48 (36.4%) .12
BSI T scores
Global Severity Index 53.6 (11.8) 50.3 (13.7) .07
Positive Symptom Distress Index 51.7 (11.0) 48.7 (12.8) .07
Positive Symptom Total 54.6 (12.5) 51.7 (14.7) .12
Age first used heroin 19 (16–25) 20 (17–25) .21
Ever injected 200 (88.5%) 107 (79.9%) .03
Ever shared injecting equipment 97 (42.9%) 57 (42.9%) 1.0
Current route of use intravenous 144 (68.3%) 64 (54.7%) .02
Previous methadone script 145 (64.4%) 76 (56.7%) .18
Previous buprenorphine script 89 (39.2%) 65 (48.5%) .10
Previous detoxification 120 (53.6%) 77 (58.3%) .44
DRR/DTTOa 41 (18.1%) 23 (17.2%) .89
DIP b 49 (21.6%) 40 (29.9%) .10
Partner drug user 72 (62.6%) 38 (49.4%) .08
Christo baseline 11.0 (0.24) 9.7 (0.32) .001 c
Brief AUDIT 3.6 (3.5) 3.5 (3.3) .84
No. illicit drugs used 4.0 (1.7) 3.5 (1.8) .01
Baseline urine test
Positive for opiate d 211 (94.6%) 122 (96.1%) .62
Positive for cocaine 97 (43.7%) 41 (32.5%) .05
Positive for amphetamine 10 (4.5%) 9 (7.1%) .33
Positive for benzodiazepine e 57 (25.6%) 26 (20.5%) .30
Positive for cannabis 90 (46.6%) 59 (56.2%) .15
a Drug rehabilitation or drug treatment and testing order.
b Drug intervention program.
c T test.
d Some opioids (e.g., street methadone/buprenorphine) give a negative opiate test on EMIT screen.
e Considering those known to be prescribed benzodiazepines as negative.
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custodial sentences, not having a drug-using parent,
being on a higher number of other medications, and the
absence of illicit benzodiazepines and cocaine from the
baseline urine (Table 3).3.8. Beliefs and knowledge regarding buprenorphine
and methadone
When participants' own beliefs about buprenorphine and
methadone were compared (i.e., within-subject comparison),
Fig. 2. Survival analysis showing retention in treatment for methadone versus buprenorphine.
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(see Table 4). Most marked differences (N1 point difference,
on each 1- to 5-point Likert scale) were taste (buprenorphine
worst), blocking effect on heroin use (buprenorphine more
effective), risk of overdose (buprenorphine safer), ease of
stopping (buprenorphine easier), and time to stop (bupre-
norphine less). Because this was a pragmatic study, we did
not have direct control over the information clinicians
discussed with subjects prior to treatment initiation.
However, subjects were asked about their sources of
information and to identify that which they considered to
be the main source in making their treatment choice. Eighty-
one percent identified their own experience as their primary
source of information (vs. 1% who identified drug workersTable 2
Reasons for participants not completing study
Reasons
Methadone
noncompleters
(n = 69)
n (%)
Buprenorphine
non-completers
(n = 77)
n (%)
Planned detox' attempt 1 (1.5) 10 (13.0)
Transferred to other service 3 (4.3) 4 (5.2)
Client dropped out 33 (47.8) 40 (51.9)
Discharged by service
Aggression 2 (2.9) 0 (0)
Tampered urine 3 (4.3) 3 (3.9)
Persistent on-top use 4 (5.8) 4 (5.2)
Other reason 3 (4.3) 3 (3.9)
Detained (police/prison) 18 (26.1) 13 (16.9)
Death 2 (2.9) 0 (0)as their primary source). In addition, subjects were asked
separately whether they felt free choose their treatment; 92%
responded that they did.
We then investigated whether those choosing buprenor-
phine as a group differed in their beliefs about the two drugs
to those choosing methadone. This analysis demonstrated
that those choosing buprenorphine appeared to have a
consistently more negative view of methadone than those
choosing methadone, whereas participants were reasonably
consistent in their view of buprenorphine irrespective of their
drug choice. In particular, those choosing buprenorphine, as
a group, believed that if they used methadone, then they
would be more likely to crave heroin, be less clear headed, be
more drowsy, and experience more emotional numbing.
They felt methadone would be harder to stop, that using
methadone was more like swapping one addiction for
another, and that they would be viewed more negatively
by others. In contrast, the only areas where there was a
difference between the two groups in views about bupre-
norphine were that those choosing methadone believed
titration on to buprenorphine would be more uncomfortable
than titration on to methadone and that craving would be less
reduced on buprenorphine (see Table 5).
Next, the relationship between beliefs and retention was
investigated. A small number of these were potentially
significant on a univariate analysis (p b .1). However, when
these were entered together into a multivariate analysis, only
one variable (belief as to whether buprenorphine blocked the
effect of heroin) remained significant after adjusting for
group, age, previous custodial sentences, parental drug user,
and cocaine use. The adjusted odds of retention were 5.21
Fig. 3. Comparing retention at 6 months by maximum dose of drug prescribed.
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buprenorphine acted as an effective blocker being more
likely to be retained than those who did not. However, it
should be noted that more than 70% of participants
considered it to be an effective blocker (retention = 63%),
whereas only 6% thought it was not (37% retention).
3.9. Reasons for choice of treatment
Reasons for choice of drug were stated by 127 of 134
(95%) of those choosing BMT and 227 of 361 (61%) of
those choosing MMT. For those stating a reason in the BMT
group, the most commonly cited reasons for choice of drug
were a negative view of methadone (52%), issues around the
drug's ability to block the effect of heroin (46%), previous
experience with buprenorphine (17%), beliefs about ease of
detoxification (12%), and issues around intoxicating effects
or a desire for clearheadedness (12%). Cited reasons did not
appear to differ between those with a positive outcome and
those with a negative outcome. For methadone, the reasons
for choice showed greater variation with by far the most
commonly cited reason being previous experience (39%),
followed by fear of withdrawal at induction (8%), issuesTable 3
Baseline variables predicting retention at 6 months on multivariate analysis
Variables
OR for
retention at
6 months 95% CI p value
Buprenorphine preferred 0.29 0.17–0.48 b.001
Age 1.05 1.01–1.08 .005
No. previous custodial sentences 0.92 0.88–0.97 .001
Parent was drug user 0.51 0.27–0.97 .04
No. of medications, M (Mdn) 1.25 1.06–1.47 .008
Baseline cocaine positive 0.56 0.34–0.93 .03
Baseline benzodiazepine positive 0.53 0.30–0.93 .03around intoxicating effects (8%) and believing that they were
on too much heroin to use buprenorphine (7%). Those citing
previous experience appeared to have a negative outcome
more often than a positive outcome (53% vs. 33%). Of
interest, all those choosing methadone because they felt they
could not take buprenorphine (due to their high level of
heroin use) dropped out of treatment (16 participants, 24% of
methadone losses).
3.10. Impact of buprenorphine availability on recruitment
Subjects choosing BMT were asked at recruitment if they
would have come into treatment if methadone were the only
treatment available, 38 (28% of the BMT group—10% of the
total sample) answered “no” to this question.
3.11. Urine results
Those prescribed buprenorphine showed evidence of
using less illicit opiate than those prescribed methadone.
The odds of having opiate-negative urine samples were
significantly higher for the buprenorphine group whether
considering all patients (OR = 2.14, 95% CI = 1.51–3.03)
or only those retained at 6 months (OR = 2.74, 95% CI =
1.77–4.22; Table 6). Evidence of sustained abstinence from
heroin was also significantly more likely in the BMT group.
Two proxy measures for this were used. First, a complete
set of six opiate-negative urine results, and then less
stringent criteria including those with five negative and one
missing urine result. On either of these measures, the
buprenorphine group was more likely to achieve sustained
abstinence. This difference was most marked in those
retained at 6 months (OR = 6.08, 95% CI = 2.15–17.16;
Table 6). No significant difference was found in urine levels
of other illicit drugs, which appeared to be unaffected by
treatment (Table 6).
Table 4
Comparing within-participant differences in views
Views
Buprenorphine,
M (Mdn)
Methadone,
M (Mdn)
No. for matched
pairs analysis
(% subjects)
p value
(Wilcoxon matched pairs)
Taste 1.7 (1) 2.9 (3) 290 (80) b.001
Withdrawal at start (5 = bad withdrawal) 3.5 (3.5) 3.0 (3) 252 (70) b.001
Hold (5 = no withdrawals) 4.2 (5) 4.4 (5) 246 (68) .05
Craving for heroin (5 = craving stopped) 3.6 (4) 3.0 (3) 248 (69) b.001
Change effect of heroin (5 = total block) 4.3 (5) 1.7 (1) 285 (79) b.001
Risk of overdose (5 = low) 3.3 (3) 1.6 (1) 173 (48) b.001
Clearheaded (5 = not at all) 1.7 (1) 2.6 (3) 258 (71) b.001
Drowsiness (5 = very sleepy) 1.8 (2) 2.8 (3) 252 (70) b.001
Emotional numbing (5 = emotional numbing) 1.9 (1) 2.8 (3) 214 (59) b.001
Others' views of addiction (5 = not addict) 2.2 (1) 1.3 (1) 308 (85) b.001
Ease of stopping drug (5 = very hard) 3.0 (3) 4.3 (5) 245 (68) b.001
Time to stop (% days/weeks vs. months) 49.3% 12.8% 219 (61) b.001 a
Swapping one addiction for another (5 = not true) 3.3 (4) 2.4 (2) 286 (79) b.001
a McNemar test for matched pairs.
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Christo data were available for almost all retained clients
at baseline, 3 months, and 6 months (94%–100% of retained
subjects). Although both groups showed an improvement in
Christo and BSI scores over follow-up, the changes adjusted
for baseline values were not significantly different between
groups. Regarding alcohol consumption, at 6 months theTable 5
Comparison of participants' views by group about buprenorphine and methadone
Views
Buprenorphine taste (5 = great)
Methadone taste (5 = great)
Importance of taste (5 = not at all)
Withdrawals experienced when starting buprenorphine (5 = yes, badly)
Withdrawals experienced when starting methadone (5 = yes, badly)
Buprenorphine stop withdrawals (hold; 5 = no withdrawals)
Methadone stop withdrawals (holds; 5 = no withdrawals)
Heroin craving when on buprenorphine (5 = expect cravings to stop)
Heroin craving when on methadone (5 = expect cravings to stop)
Change effect of heroin when on buprenorphine (5 = totally blocked)
Change effect of heroin when on methadone (5 = totally blocked)
Risk of overdose on buprenorphine (5 = low)
Risk of overdose on methadone (5 = low)
Clearheaded on buprenorphine (5 = not at all)
Clearheaded on methadone (5 = not at all)
Drowsiness on buprenorphine (5 = very sleepy)
Drowsiness on methadone (5 = very sleepy)
Emotional numbing effect of buprenorphine (5 = disconnected from emotions)
Emotional numbing effect of methadone (5 = disconnected from emotions)
View of other people about buprenorphine (5 = not a drug addict)
View of other people about methadone (5 = not a drug addict)
Ease of stopping buprenorphine (5 = very hard)
Ease of stopping methadone (5 = very hard)
How long to stop buprenorphine (% days or weeks vs. months)
How long to stop methadone (% days or weeks as opposed to months)
Buprenorphine is swapping one addiction for another (5 = not true)
Methadone is swapping one addiction for another (5 = not true)
Importance of receiving a drug experienced beforeBMT group showed an improvement (decrease in AUDIT
scores), whereas the MMT group demonstrated deterioration
(increased scores; p = .052 between groups; see Table 7).
3.13 Side effects
A greater proportion of those receiving methadone
complained of side effects than those receiving buprenorphinetreatment
Buprenorphine group,
M (SD)
Methadone group,
M (SD)
p value
(Mann–Whitney test)
1.8 (0.9) 1.7 (0.8) .05
3.1 (1.1) 2.8 (1.1) .006
4.2 (1.3) 3.8 (1.3) .01
3.2 (1.1) 3.7 (1.3) b.001
2.5 (1.3) 3.2 (1.2) b.001
4.2 (1.0) 4.1 (1.1) .55
4.2 (1.0) 4.4 (0.9) .19
3.9 (1.1) 3.4 (1.5) .001
2.6 (1.3) 3.2 (1.3) b.001
4.5 (0.9) 4.3 (1.1) .15
1.5 (0.9) 1.8 (1.1) .04
3.4 (1.5) 3.2 (1.5) .46
1.7 (1.0) 1.6 (1.0) .40
1.7 (0.8) 1.7 (1.0) .84
3.1 (1.2) 2.3 (1.0) b.001
1.9 (0.9) 1.7 (1.0) .14
3.4 (1.2) 2.5 (1.1) b.001
1.9 (1.1) 1.8 (1.1) .19
3.4 (1.3) 2.5 (1.2) b.001
2.2 (1.4 2.2 (1.5) .63
1.2 (0.7) 1.4 (0.9) .04
2.8 (1.2) 3.1 (1.3) .09
4.6 (0.8) 4.2 (0.9) b.001
50.5% 48.1% .71
11.2% 17.3% .16
3.4 (1.4) 3.2 (1.5) .37
1.9 (1.2) 2.7 (1.5) b.001
3.0 (1.6) 2.7 (1.6) .11
Table 6
Urine test results: repeated measures analysis and analysis of opiate abstinence
Variables
All subjects Subjects retained at 6 months
No. of tests
OR of a negative urine
sample for the BMT vs.
MMT group (95% CI) p value No. of tests
OR of a negative urine
sample for the BMT vs.
MMT group (95% CI) p value
Opiate 1,400 2.136 (1.509–3.027) .000 1,122 2.735 (1.771–4.224) .000
Cocaine 1,400 1.514 (0.989–2.318) .056 1,122 1.331 (0.766–2.313) .311
Amphetamine 1,395 0.809 (0.364–1.794) .601 1,121 0.771 (0.260–2.290) .640
Benzodiazepines 1,395 1.262 (0.745–2.137) .388 1,120 1.350 (0.670–2.718) .401
Cannabis 1,199 1.166 (0.722–1.884) .529 969 1.432 (0.782–2.624) .245
OR BMT vs. MMT
groups (95% CI)
OR BMT vs. MMT
groups (95% CI)
Opiate abstinence (6 negative urines) 2.693 (1.071–6.767) .04 6.079 (2.153–17.163) .001
Opiate abstinence (6 negative urines
or 5 negative + 1 missing)
2.391 (1.122–5.096) .02 4.748 (2.081–10.831) .03
349H. Pinto et al. / Journal of Substance Abuse Treatment 39 (2010) 340–352(55% vs. 44%, p = .01). The most common side effects in the
MMT group were sweating (19%), sedation (12%), and
constipation (10%). Side effects most frequently reported in
the BMT group were sedation (9%) and constipation (8%).
3.14. Adverse events
Two patients died during the trial period, both in the
methadone group. One death was due to a heroin overdose
shortly after the start of treatment related to adverse social
circumstances. The second was recorded as methadone
toxicity in combination with two other sedative drugs in a
patient prescribed the same dose for some time.4. Discussion
This is the first large study to compare the effectiveness
of buprenorphine maintenance with methadone maintenance
in ordinary UK clinical practice. The results demonstrate
that those treated with buprenorphine are more than 50%
less likely to remain in treatment for 6 months than those
receiving methadone (adjusted hazard ratio = 0.47, 95% CI
= 0.32–0.69, p b .001). This is considerably greater than the
effect size pooled from randomized controlled trials
(relative risk = 0.85) by Mattick et al. (2008) and similar
to that Burns et al. (2009) found in a large (nonrandomized)
retrospective cohort study. However, this poorer retention
needs to be balanced against a finding of superiority in
suppression of illicit opiate use by buprenorphine in those
who were retained. This was demonstrated in several ways
including an overall reduction in the number of urine
samples positive for opiates, increased rates of sustained
abstinence from illicit use, and increased rates of progres-
sion to detoxification. These findings are in contrast to
previous randomized trials but similar to the results that
Vigezzi et al. (2006) found in another nonrandomized,
nonblinded field trial. In addition, our results suggest that
BMT may be associated with reduced alcohol use but didnot demonstrate any difference in social functioning or
psychological health.
The hypothesis that poor retention is due to slow titration
or inadequate dosing is not supported by the results of this
trial. Rapid titration was achieved, and although loss during
titration was more common in the BMT group and made a
small contribution to the overall outcome, an increased rate
of loss was seen throughout the trial. The mean maximum
doses of buprenorphine achieved (11.7 mg) were slightly
below the current UK guidelines (12–16 mg for most
patients; DOH, 2007) but in the upper range of the doses
used in the flexible dosing trials Mattick et al. (2008)
included in the Cochrane review, almost identical to
estimated average doses found in Australian clinical practice
by Burns et al. (2009) but above the average dose (8.9 mg)
found in a recent national audit of actual prescribing 2004–
2005 by the NTA (2007). Dosing was flexible, and subjects
did not appear to seek higher doses. In fact, more of those on
buprenorphine chose to reduce their dose than to increase it.
Furthermore, our results suggest that above 8 mg increasing
doses for buprenorphine did not improve retention. No
studies to date have specifically compared retention for doses
greater than 8 mg, but four studies, which examined dose of
buprenorphine as a predictor of retention in a secondary
analysis, failed to find a relationship (Gerra et al., 2004,
2006; Soyka, Zingg, Koller, & Kuefner, 2008; Vigezzi et al.,
2006). Kakko et al. (2007) reported 78% retention using a
very high mean dose (29 mg), but this was an intention-to-
treat analysis where only 35% of the BMT group actually
remained on buprenorphine at 6 months.
Examination of predictors of retention in the sample as a
whole revealed treatment of choice as by far the strongest
factor. Additional predictors (older age, fewer custodial
sentences, and absence of drug-using parents), although less
powerful, made intuitive sense. Additional use of benzodia-
zepines and cocaine/crack is known to negatively effect
prognosis (Marsden et al., 2009; Rooney, Kely, Bamford,
Sloan, & O'Connor, 1999). The use of more prescribed
medications was surprising but could imply more engage-
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consequences of drug use leading to greater motivation to
engage. The numbers retained were too small to confidently
examine baseline predictors of retention in the buprenor-
phine group separately. Previous studies, which have
examined baseline factors, identified comorbid depression
and chronicity of dependence, but these have not been
successfully replicated (Gerra et al., 2004, 2006; Poirier
et al., 2004; Schottenfield, Pakes, & Kosten, 1998; Soyka
et al., 2008).
Rather than any simple demographic variable, an
alternative hypothesis is that the disparity in retention
between methadone and buprenorphine is more closely
related to the match between individuals' needs, treatment
aspirations, and expectations.
Firstly, with regard to aspiration, maintenance treatment
is usually considered as a route to abstinence from illicit drug
use. However, for some injecting drug users, it may be seen
as a means to reestablish control over their use, allowing
them to comfortably forgo alternative opiates (usually
heroin) but retain the option to use occasionally, either
recreationally or as a coping strategy. Although possible, this
is less easy for those using buprenorphine, a drug that blocks
opiate receptors. It is possible, therefore, that more of those
choosing methadone did so with these more achievable
aspirations. The finding that retention was prolonged in
those who expressed stronger baseline beliefs about
buprenorphine as a “blocker” with less intoxicating effects,
and chose not to take it, supports such a hypothesis.
Furthermore, those choosing methadone commonly cited
fear of withdrawal and issues around desire for expected
opioid effects as reasons for choosing it.
In contrast, apart from a dislike of methadone, those
choosing buprenorphine commonly cited its ability to block
heroin use, ease of detoxification, and lack of intoxicating
effects as reasons for their choice. This may reflect higher
aspirations around elimination of illicit opiate use and
detoxification. A previous study (Pinto, Rumball, &
Holland, 2008) found that buprenorphine is often viewed
as a drug for those who are “serious” about treatment.
Although this would explain the better performance in this
group regarding illicit opiate use, it would also leave those
individuals who failed to achieve these more challenging
goals vulnerable to disillusionment and disengagement.
Secondly buprenorphine is intrinsically less rewarding than
methadone and provides less sedative effect. This might have
been expected to be of particular value to those expressing
more psychological distress, but BSI scores did not predict
retention in this study. Finally, because of its reduced
potency, a prescription for buprenorphine may simply be
easier for subjects to disengage from than high-dose
methadone.
The numbers lost to treatment on BMT are of concern,
and the authors suggest that further research should focus on
the relationship between treatment aspirations, treatment
choice, and retention in treatment.
351H. Pinto et al. / Journal of Substance Abuse Treatment 39 (2010) 340–352Exploration of subjects' views about the drugs revealed
that they are generally very well informed, with the largest
perceived differences between the drugs being in taste,
ability to block heroin use, and ease of coming off the drug.
The stated reasons for choice, in addition to aspirations,
revealed more about what is perceived to be important. Past
experience was commonly cited by both groups, but safety
was rarely mentioned, highlighting the mismatch in priorities
between patients and their clinicians.
The pragmatic, open-label design of this study has
strengths and weaknesses. A very high recruitment rate
was achieved (89% of the eligible population), and subjects
received the treatment available in ordinary National Health
Service (NHS) community drug services. This makes the
results highly generalizable. However, the limitations must
be acknowledged. The absence of randomization is one
limitation. Although the groups appeared similar on most
baseline variables, there were some differences between
groups. These differences suggested that the methadone
group had more risk factors for poor retention. Despite this,
adjustment for baseline differences only increased the gap in
retention rates between BMT and MMT. Nevertheless, we
cannot be certain that unmeasured differences did not favor
the methadone group. No measures were taken to reduce the
possible impact of the views and expectations of treating
staff and subjects because these are inevitably present and
contribute to effectiveness in real clinical practice. In
addition, we deliberately included an exploration of subjects'
beliefs and expectations as a part of our study. Furthermore,
because of the pragmatic nature of the trial, we were unable
to dictate the frequency of urine sampling. As a result, our
data are restricted to one per month, which gives only a
limited picture of possible drug use and therefore weakens
the findings regarding suppression of illicit use.
The marked difference in retention rates raises important
issues regarding the use of buprenorphine for maintenance
in the UK, where commissioners have imposed targets of
80% retention at 3 months, linked to funding (BMT falls
below this at 61.2%, whereas MMT reaches 84.1%). In
addition, buprenorphine is more expensive than methadone.
However, the extra cost may be offset for services (treatment
is free for NHS patients) if BMT increases progression to
abstinence and detoxification allowing shorter episodes of
treatment. Our results also provide evidence that the
availability of buprenorphine recruits additional individuals
into treatment. Not only did 10% of the sample state that
they would not have entered treatment where methadone is
the only available option, but all of those accepting MMT
because they thought they could not be titrated on to BMT
dropped out of treatment. In addition, the group choosing
BMT expressed a more negative view of methadone, and
more than half cited dislike of methadone as the reason they
chose buprenorphine. This would suggest that although
buprenorphine should, as per NICE Guidance, be an
available option for all, services should closely monitor
those on this drug for the first 3 months and maintain a lowthreshold for conversion to methadone for those not
achieving illicit abstinence.
In conclusion, this study has shown that in a UK drug
treatment context, those choosing methadone maintenance
are considerably more likely to be retained in treatment at
6 months than those choosing buprenorphine. This
difference appears unrelated to dose, titration procedure,
or subjects' beliefs and expectations about the drugs.
Those retained on buprenorphine appear more able to
suppress illicit opiate use and progress to detoxification. In
addition, provision of buprenorphine has merits in
increasing recruitment to treatment.5. Addresses of sites
Trust Alcohol and Drug Service, NWMHPT, Norfolk,
England:
• 7 Unthank Road , Norwich NR2 2PA,
• 22-24 Colgate, Norwich NR3 1BQ
• The Weavers Centre, Hellesdon Hospital, Drayton
High Road, Norwich and
• The Willows Centre, Northgate Hospital, Northgate,
Great Yarmouth.
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